세계의 항섬유소 용해제 시장 : 예측(2025-2030년)

The global anti-fibrinolytic drug market is anticipated to grow at a CAGR of 6.77%, increasing from US$37.354 billion in 2025 to US$51.827 billion by 2030.

Antifibrinolytic drugs are designed to slow the dissolution of blood clots, making them essential for treating heavy menstrual bleeding and other types of hemorrhages. These agents play a critical role in preventing clot degradation in areas prone to fibrinolysis, such as the nasal cavity, oral cavity, and female reproductive tract. The demand for antifibrinolytic drugs is particularly strong in hospitals and clinics, where most surgeries occur. As the number of surgical procedures increases globally, the need for these medications to manage bleeding effectively is expected to drive market growth.The global antifibrinolytic drug market is anticipated to expand due to several factors, including a rise in bleeding disorders, an increase in trauma and surgical incidents, technological advancements, and a growing elderly population. These factors create a heightened demand for antifibrinolytic medications to manage bleeding episodes, control blood loss in trauma situations, and improve treatment efficacy and safety. The aging population is especially vulnerable to bleeding disorders and their complications, further increasing the need for these drugs.

Key Drivers of the Global Antifibrinolytic Drug Market:

1. Surge in Surgical Procedures: The increasing number of surgeries worldwide is a primary driver of market growth. Antifibrinolytic drugs are crucial during various surgical operations, including cardiovascular and dental procedures, as they help minimize bleeding.

2. Rise in Road Traffic Accidents: The World Health Organization (WHO) estimates that approximately 1.35 million fatalities occur annually due to road traffic accidents. Given that these drugs prevent clot lysis and mitigate blood loss, their demand is significantly influenced by the rising incidence of road injuries.

3. Management of Menorrhagia: The growing use of antifibrinolytic drugs among women to control heavy menstrual flow contributes to market expansion.

4. Technological Advancements: Innovations in drug formulations and delivery mechanisms enhance treatment effectiveness and safety.

Geographical Insights:

• North America: This region is expected to hold a significant share of the antifibrinolytic drug market due to the presence of major pharmaceutical companies and a high prevalence of surgeries. The adoption of these drugs for managing menstrual flow also plays a key role in market growth.
• Asia-Pacific (APAC): The APAC region is projected to experience substantial growth due to a high rate of road traffic injuries and accidents. With approximately 645,000 lives lost each year from road accidents in this region, there is a strong demand for antifibrinolytic medications. Additionally, increased health awareness among women regarding menstrual health further drives market growth.

In summary, the global antifibrinolytic drug market is poised for significant growth driven by surgical demands, rising accident rates, advancements in medical technology, and demographic factors such as an aging population.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-fibrinolytic drug market is segmented and analyzed as below:

By Indication

• Surgeries
• Cardiac
• Dental
• Others
• Menorrhagia
• Hereditary Angioedema (HAE)

By Route of Administration

• Oral
• Injection

By End-User

• Hospital and Clinics
• Ambulatory Surgical Centers

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY INDICATION

• 5.1. Introduction
• 5.2. Surgeries
  • 5.2.1. Cardiac
  • 5.2.2. Dental
  • 5.2.3. Others
• 5.3. Menorrhagia
• 5.4. Hereditary Angioedema (HAE)

6. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Oral
• 6.3. Injection

7. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospital and Clinics
• 7.3. Ambulatory Surgical Centers

8. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Indication
  • 8.2.2. By Route of Administration
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Indication
  • 8.3.2. By Route of Administration
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Indication
  • 8.4.2. By Route of Administration
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. UK
    • 8.4.4.4. Spain
    • 8.4.4.5. Italy
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Indication
  • 8.5.2. By Route of Administration
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. By Indication
  • 8.6.2. By Route of Administration
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. Japan
    • 8.6.4.2. China
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Pfizer Canada ULC
• 10.2. Zydus Pharmaceuticals, Inc.
• 10.3. Viatris Inc.
• 10.4. Xanodyne Pharmaceuticals, Inc.
• 10.5. American Regent, Inc. (Daiichi Sankyo Group)
• 10.6. Kedrion Biopharma
• 10.7. Bayer
• 10.8. Grifols
• 10.9. CSL Behring